Completed × Arsenic Trioxide × Other hematologic neoplasm × Clear all Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia
Phase 1 Completed
12 enrolled
TUD-APOLLO-064
Phase 3 Completed
135 enrolled
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Phase 2 Completed
78 enrolled 8 charts
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Phase 3 Completed
106 enrolled 14 charts
APL0406
Phase 3 Completed
276 enrolled
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Phase 2 Completed
17 enrolled 8 charts
Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS
Phase 2 Completed
92 enrolled
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder
Phase 2 Completed
15 enrolled
All-trans Retinoic Acid, and Arsenic +/- Idarubicin
Phase 2 Completed
78 enrolled 10 charts
Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector
Phase 2 Completed
50 enrolled 7 charts
Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes
Phase 2 Completed
30 enrolled 7 charts
Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma
Phase 1 Completed
Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
Phase 4 Completed
60 enrolled
Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia
Phase 2 Completed
Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
Phase 1 Completed
61 enrolled
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase 2/3 Completed
2,000 enrolled
Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
Phase 1 Completed
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia
Phase 2 Completed
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 2 Completed
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma
Phase 2 Completed
Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
Phase 3 Completed
420 enrolled
Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Phase 1/2 Completed
Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia
Phase 1 Completed
13 enrolled
Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia
Phase 1/2 Completed
13 enrolled
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
Phase 2 Completed
35 enrolled
Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia
Phase 2 Completed
11 enrolled
Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Phase 1/2 Completed
16 enrolled
Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes
Phase 1/2 Completed
32 enrolled
A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec
Phase 2 Completed
6 enrolled
Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2 Completed
41 enrolled
Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide
Phase 2 Completed
10 enrolled